Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 401–500 of 1,000
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 32
Sun, Z., Zheng, F., Wu, S., Liu, Y., Guo, H., & Liu, Y. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.018 · Cited by 31
Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 31
An overview of the role of carfilzomib in the treatment of multiple myeloma
Ziogas, D. C., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1404575 · Cited by 31
Self-citationCardiovascular adverse events in multiple myeloma patients
Heckmann, M. B., Doroudgar, S., Katus, H. A., & Lehmann, L. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.87 · Cited by 32
“Significantly improved overall response rates, even when compared to bortezomib, lead to FDA and European Medicines Agency (EMA) approval of carfilzomib in 2012 and 2016, respectively (8,9).”
BackgroundVariable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)
Cleynen, A., Samur, M., Perrot, A., Buisson, L., Mahéo, S., Fulciniti, M., Attal, M., Munshi, N. C., Avet‐Loiseau, H., & Corre, J. (2018) · Blood · doi:10.1182/blood-2018-09-876433 · Cited by 31
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0495-9 · Cited by 29
Trudel, S., Moreau, P., & Touzeau, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s174640 · Cited by 30
“For the treatment of patients with RRMM, lenalidomide has also been studied in combination with carfilzomib (KRd), ixazomib (IRd) and daratumumab (DaraRd).(8,33,35) In terms of response PFS, the triplet DaraRd led to better results in comparison with Elo-Rd, with similar safety profiles.”
ResultSelf-citationProteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells
Woodle, E. S., Tremblay, S., Brailey, P. A., Girnita, A. L., Alloway, R. R., Aronow, B. J., Dasgupta, N., Ebstein, F., Kloetzel, P., Lee, M. J., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15634 · Cited by 29
Mehta–Shah, N., Lunning, M. A., Moskowitz, A. J., Boruchov, A. M., Ruan, J., Lynch, P., Hamlin, P. A., Leonard, J. P., Matasar, M. J., Myskowski, P. L., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26288 · Cited by 30
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 31
“0001), and improvement was shown in the response rate, depth of response, and patient-reported quality of life (QoL) metrics, with tolerable toxicity [40].”
BackgroundSteroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
King, T., & Faiman, B. M. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.240-249 · Cited by 32
“ORG almost every clinical trial treating MM (Lonial et al., 2015; Palumbo et al., 2014; Stewart et al., 2015).”
BackgroundVandewynckel, Y., Coucke, C., Laukens, D., Devisscher, L., Paridaens, A., Bogaerts, E., Vandierendonck, A., Raevens, S., Verhelst, X., Steenkiste, C. V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9222 · Cited by 31
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
“Carfilzomib (K) KRd Adult patients with MM who have received at least one previous regimen [7,19]”
BackgroundPatient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
Sparano, F., Cavo, M., Niscola, P., Caravita, T., & Efficace, F. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4137-x · Cited by 28
Advancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 29
Wilke, T., Mueller, S., Bauer, S., Pitura, S., Probst, L., Ratsch, B. A., & Salwender, H. J. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s183187 · Cited by 28
“To confront patients with realistic, although hypothetical choices, treatment-associated attribute levels were derived from either the SmPCs (application mode) or data reported in the respective clinical trials addressing new generation PIs (progression-free time and the MIN and MAX grade $3 AE frequencies).(1,3,5) In…”
BackgroundMethodPatel, V. G., & Cornell, R. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0784-4 · Cited by 30
Brown, S., Sherratt, D., Hinsley, S., Flanagan, L. M., Roberts, S., Walker, K., Hall, A., Pratt, G., Messiou, C., Jenner, M. W., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046225 · Cited by 29
Daratumumab: A review of current indications and future directions
Hill, E., Morrison, C., & Kazandjian, D. G. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.008 · Cited by 28
Fradley, M. G., Groarke, J. D., Laubach, J. P., Alsina, M., Lenihan, D. J., Cornell, R. F., Maglio, M. E., Shain, K. H., Richardson, P. G. G., & Moslehi, J. J. (2017) · British Journal of Haematology · doi:10.1111/bjh.14970 · Cited by 28
Triplet vs. doublet drug regimens for managing multiple myeloma
Offidani, M., Corvatta, L., & Gentili, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1418856 · Cited by 28
“The ASPIRE trial [56] compared the efficacy and safety of the combination of carfilzomib, lenalidomide, and dexamethasone (KRd) with lenalidomide and dexamethasone regimen.”
BackgroundMethodDimopoulos, M. A., Kaufman, J. L., White, D. J., Cook, G., Rizzo, M., Xu, Y., Fahrbach, K. R., Gaudig, M., Slavcev, M., Dearden, L., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.011 · Cited by 31
Self-citationGavazzoni, M., Lombardi, C., Vizzardi, E., Gorga, E., Sciatti, E., Rossi, L., Belotti, A., Rossi, G., Metra, M., & Raddino, R. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.014 · Cited by 28
Conticello, C., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Sapienza, G., Leotta, V., Parisi, M. S., Markovic, U., Garibaldi, B., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060877 · Cited by 29
“2019, 8, 877 13 of 16 ORR was lower than what previously reported in the ASPIRE trial (61 versus 87%), with a comparable proportion of patients in CR [5].”
BackgroundResultInfluentialSequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000109 · Cited by 27
Moreau, P., Kumar, S. K., Boccia, R. V., Iida, S., Goldschmidt, H., Cocks, K., Trigg, A., Zahlten‐Kumeli, A., Yücel, E., Panjabi, S. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0480-2 · Cited by 27
Self-citationHerpesvirus Infections Potentiated by Biologics
Ho, D. Y., Enriquez, K. T., & Multani, A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.006 · Cited by 31
Use of daratumumab in high risk multiple myeloma: A meta‐analysis
Premkumar, V. J., Pan, S. M., Lentzsch, S., & Bhutani, D. (2020) · eJHaem · doi:10.1002/jha2.47 · Cited by 27
“05) in the ASPIRE trial [12] as well as the ELOQUENT-2 trial comparing elotuzumab with RD to RD alone with a HR of 0.”
MethodThe role of carfilzomib in relapsed/refractory multiple myeloma
Yee, A. J. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211019612 · Cited by 28
Molecular mechanisms for vascular complications of targeted cancer therapies
Gopal, S., Miller, K. B., & Jaffe, I. Z. (2016) · Clinical Science · doi:10.1042/cs20160246 · Cited by 27
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Michallet, M., Chapuis‐Cellier, C., Dejoie, T., Lombard, C., Caillon, H., Sobh, M. A. K., Moreau, P., Attal, M., & Avet‐Loiseau, H. (2017) · Leukemia · doi:10.1038/leu.2017.209 · Cited by 28
Self-citationAvet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 27
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
Lee, D. H., & Fradley, M. G. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0618-y · Cited by 27
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 28
Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 32
Mikhael, J. R., Manola, J. B., Dueck, A. C., Hayman, S. R., Oettel, K. R., Kanate, A. S., Lonial, S., & Rajkumar, S. V. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0110-7 · Cited by 27
Self-citationByun, J. M., Yoon, S., Koh, Y., Kim, I., Jo, J., Park, H., Lee, J., & Lee, J. (2019) · Anticancer Research · doi:10.21873/anticanres.13712 · Cited by 27
Pandey, M. K., Gowda, K., Sung, S., Abraham, T., Budak-Alpdoǧan, T., Talamo, G., Dovat, S., & Amin, S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.06.003 · Cited by 28
Ixazomib: a novel drug for multiple myeloma
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1518129 · Cited by 30
Spur, E.-M., Althof, N., Respondek, D., Klingel, K., Heuser, A., Overkleeft, H. S., & Beling, A. (2016) · Toxicology · doi:10.1016/j.tox.2016.04.010 · Cited by 26
Salvage second transplantation in relapsed multiple myeloma
Dhakal, B., D’Souza, A., Kleman, A., Chhabra, S., Mohan, M., & Hari, P. (2020) · Leukemia · doi:10.1038/s41375-020-1005-8 · Cited by 26
“In the relapsed setting, there are several key trials with the backbone of lenalidomide and dexamethasone (Rd), specifically carfilzomib-Rd (KRd) (ASPIRE) [7]; daratumumabRd (DRd) (POLLUX) [8], daratumumab with bortezomib and dexamethasone (CASTOR) [9], and several newer immunotherapeutic approaches CAR-Ts, ADCs, and…”
BackgroundImmunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 29
Zhang, T., Wang, Y., Wang, B., Jin, W., Xia, Y., Liu, C., & Zhang, Y. (2022) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202101506 · Cited by 26
Yamamoto, C., Minakata, D., Koyama, S., Sekiguchi, K., Fukui, Y., Murahashi, R., Nakashima, H., Matsuoka, S., Ikeda, T., Kawaguchi, S., et al. (2022) · Blood · doi:10.1182/blood.2021015220 · Cited by 26
The start of a new wave: Developments in proteasome inhibition in multiple myeloma
Yong, K., Gonzalez‐McQuire, S., Szabó, Z. R., Schoen, P., & Hájek, R. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13071 · Cited by 26
Self-citationSweiss, K. I., Wirth, S., Sharp, L. K., Park, I., Sweiss, H., Rondelli, D., & Patel, P. R. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00085 · Cited by 29
Managing multiple myeloma in elderly patients
Diamond, E., Lahoud, O. B., & Landau, H. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1365859 · Cited by 27
“In the ASPIRE trial [36], KRD (for 18 cycles) followed by RD was compared with RD in 792 patients with relapsed MM.”
BackgroundMethodBringhen, S., Mina, R., Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., Offidani, M., Spada, S., Benevolo, G., Ponticelli, E., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.208272 · Cited by 25
“In the ASPIRE study, carfilzomib was tested at the dose of 27 mg/m(2).(13) However, a higher dose of carfilzomib (36 mg/m(2)) had been investigated in combination with lenalidomide and dexamethasone, and was shown to be safe and effective for NDMM patients.”
MethodSelf-citationProgression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
Pawlyn, C., Schjesvold, F. H., Cairns, D. A., Wei, L., Davies, F. E., Nadeem, O., Abdulhaq, H., Mateos, M., Laubach, J. P., Weisel, K. C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01109-4 · Cited by 25
Self-citationSmith, E. L., Devlin, S. M., Kosuri, S., Orlando, E. H., Landau, H. J., Lesokhin, A. M., Chung, D. J., Hassoun, H., Lendvai, N. K., Landgren, O., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.08.025 · Cited by 25
Current therapeutic strategies for multiple myeloma
Torimoto, Y., Shindo, M., Ikuta, K., & Kohgo, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0826-3 · Cited by 27
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 27
“Direct to Drug” screening as a precision medicine tool in multiple myeloma
de Campos, C. B., Meurice, N., Petit, J. L., Polito, A. N., Zhu, Y. X., Wang, P., Bruins, L. A., Wang, X., Armenta, I. D. L., Darvish, S. A., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0320-7 · Cited by 26
Self-citationMiguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
“0001) vs lenalidomide plus dexamethasone (Table 2) [18].”
BackgroundSelf-citationHájek, R., Jarkovský, J., Maisnar, V., Pour, L., Špıčka, I., Minařík, J., Gregora, E., Kessler, P., Sýkora, M., Fraňková, H., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.04.003 · Cited by 24
Self-citationProgression with clinical features is associated with worse subsequent survival in multiple myeloma
Chakraborty, R., Liu, H. D., Rybicki, L. A., Tomer, J., Khouri, J., Dean, R. M., Faiman, B. M., Kalaycio, M. E., Samaras, C. J., Majhail, N. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25415 · Cited by 24
Gomez-Arteaga, A., Mark, T. M., Guarneri, D., Christos, P. J., Gergis, U. S., Greenberg, J., Hsu, J., Mayer, S. A., Niesvizky, R., Pearse, R. N., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0587-0 · Cited by 24
Self-citationRapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 25
Tan, C. R. C., Derkach, A., Nemirovsky, D., Ciardiello, A. K., Diamond, B. T., Hultcrantz, M. L., Hassoun, H., Mailankody, S., Shah, U. A., Maclachlan, K. H., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00882-y · Cited by 25
Yang, X., Zhou, Y., Tan, S., Tian, X., Meng, X., Li, Y., Zhou, B., Zhao, G., Ge, X., He, C., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.04.008 · Cited by 25
Self-citationPrimary Plasma Cell Leukemia: Identity Card 2016
Musto, P., Simeon, V., Todoerti, K., & Neri, A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0392-6 · Cited by 24
Multiple Myeloma Minimal Residual Disease
Paiva, B., García‐Sánz, R., & Miguel, J. F. S. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_7 · Cited by 27
Hari, P., Mateos, M., Abonour, R., Knop, S. T., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D. S. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.122 · Cited by 24
Self-citationJakubowiak, A. J., Houisse, I., Majer, I. M., Benedict, Á., Campioni, M., Panjabi, S. S., & Ailawadhi, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1391088 · Cited by 24
Self-citationShah, J. J., Usmani, S. Z., Stadtmauer, E. A., Rifkin, R. M., Berenson, J. R., Berdeja, J. G., Lyons, R. M., Klippel, Z. K., Chang, Y., & Niesvizky, R. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.05.017 · Cited by 24
Self-citationQuality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
Martino, M. V., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P. F., et al. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1634541 · Cited by 25
“Moreover, the, results of a quadruplet regimen showed that patients achieved deeper and faster responses with the CARF/LENA quadruplet compared with an immunomodulatory agent–based triplet, with 80% of patients achieving a complete response or very good partial response at the end of induction [48].”
MethodInfluentialCohen, Y. C., Magen, H., Lavi, N., Gatt, M. E., Chubar, E., Horowitz, N. A., Kreiniz, N., Tadmor, T., Trestman, S., Vitkon, R., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03985-9 · Cited by 24
Luo, X., Du, X., Li, J.-L., Liu, X., & Meng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s166640 · Cited by 23
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
Kegyes, D., Gulei, D., Drulă, R., Cenariu, D., Țigu, A. B., Dima, D. M., Tănase, A., BADELITA, S. N., Buzoianu, A. D., Ciurea, S. O., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101100 · Cited by 25
Grynblat, J., Khouri, C., Hlavaty, A., Jaïs, X., Savale, L., Chaumais, M., Kularatne, M., Jevnikar, M., Boucly, A., Antigny, F., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.02158-2023 · Cited by 23
Mukhopadhyay, P., Abdullah, H. A., Opalinska, J., Paka, P., Richards, E., Weisel, K. C., Trudel, S., Mateos, M., Dimopoulos, M. A., & Lonial, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01212-0 · Cited by 23
Self-citationGiannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 30
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 26
“Patients with progressive disease during prior bortezomib treatment were also excluded [11].”
BackgroundMethodInfluentialSelf-citationSafety of ixazomib for the treatment of multiple myeloma
Bonnet, A., & Moreau, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344212 · Cited by 23
“These results led to the FDA approval of the first PI in RRMM patients in May 2003, before the European Union (EU) followed in April 2004.”
BackgroundResultInfluentialSelf-citationRole of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Leleu, X. P., Martin, T. G., Einsele, H., Lyons, R. M., Durie, B. G. M., Iskander, K. S., & Ailawadhi, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.016 · Cited by 24
Mele, A., Prete, E., Risi, C. D., Citiso, S., Greco, G., Falcone, A. P., Sanpaolo, G., Mele, G., Giannotta, A., Vergine, C., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04329-3 · Cited by 25
Hájek, R., Minařík, J., Štraub, J., Pour, L., Jungová, A., Berdeja, J. G., Boccadoro, M., Brožová, L., Spencer, A. G., van Rhee, F., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1225 · Cited by 24
Self-citationFlow Cytometric MRD Detection in Selected Mature B-Cell Malignancies
Böttcher, S., Ritgen, M., & Kneba, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-269-8_9 · Cited by 24
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A. Z., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx160 · Cited by 25
“3% in the control arm) [91]; 5% with ixazomib, lenalidomide, and dexamethasone (versus 4% in the control arm) [92]; 2.”
BackgroundSelf-citationRaje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease
Ashjian, E. J., & Redic, K. A. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215572036 · Cited by 24
“0001).(25) The most common AEs (occurring in greater than 30% of patients) include thrombocytopenia, fatigue, anemia, nausea, dyspnea, diarrhea, and pyrexia.”
BackgroundGupta, N., Yang, H., Hanley, M. J., Zhang, S., Liu, R., Kumar, S. K., Richardson, P. G. G., Skácel, T., & Venkatakrishnan, K. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0524-3 · Cited by 24
“The overlapping mechanisms of action of proteasome inhibitors and immunomodulatory drugs, including nuclear factor-kappa B inhibition, caspase-mediated apoptosis, and inhibition of myeloma cell migration and angiogenesis [23–27], have been shown to have synergistic activity in myeloma [26–29], with proteasome inhibito…”
BackgroundShah, C., Bishnoi, R., Wang, Y., Zou, F., Bejjanki, H., Master, S. R., & Moreb, J. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25281 · Cited by 24
“A total of 7 clinical trials used Carf in combination with other agents, such as Dexa in four studies [12, 15, 16, 25], Len and Dexa in two studies [21, 24] and panobinostat in one study [13] as shown in Tables 1–3.”
BackgroundMethodChallenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00500-4 · Cited by 24
Astarita, A., Mingrone, G., Airale, L., Vallelonga, F., Covella, M., Catarinella, C., Cesareo, M., Bruno, G., Leone, D., Giordana, C., et al. (2021) · Cancers · doi:10.3390/cancers13071631 · Cited by 23
Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review
Madanat, L., Gupta, R., Weber, P., Kumar, N., Chandra, R., Ahaneku, H. P., Bansal, Y., Anderson, J., Bilolikar, A., & Jaiyesimi, I. A. (2022) · Current Cardiology Reviews · doi:10.2174/1573403x18666220531094800 · Cited by 24
“The rate of heart failure rate was 3.8% for KRd compared to 1.8% for Rd, and ischemic heart disease rates were 3.3% for KRd compared to 2.1% in the Rd group [99].”
ResultInfluentialNew Developments in Myeloma Treatment and Response Assessment
Kraeber‐Bodéré, F., Jamet, B., Bezzi, D., Zamagni, E., Moreau, P., & Nanni, C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264972 · Cited by 23
Self-citationHabib, C. N., Ali, A. E., Anber, N. H., & George, M. Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122245 · Cited by 23
Surgical Treatment of Uterine Fibroids Within a Containment System and Without Power Morcellation
Kho, K. A., & Brown, D. (2015) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000168 · Cited by 22
Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 23
Maiese, E. M., Evans, K. A., Chu, B. C., & Irwin, D. E. (2018) · Europe PMC (PubMed Central) · Cited by 22
Wildes, T. M., & Anderson, K. C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.88 · Cited by 24
Rahmadian, A. P., Santos, S. D., Parshad, S., Everest, L., Cheung, M. C., & Chan, K. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7362 · Cited by 22
Ball, S., Behera, T. R., Anwer, F., & Chakraborty, R. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04062-x · Cited by 22
Current and Novel Alkylators in Multiple Myeloma
Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 26
Self-citationProteasome Inhibitors as a Potential Cause of Heart Failure
Koulaouzidis, G., & Lyon, A. R. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.12.001 · Cited by 21
Lecat, C. S. Y., Taube, J. B., Wilson, W., Carmichael, J., Parrish, C., Wallis, G., Kyriakou, C. A., Lee, L. S. H., Mahmood, S., Papanikolaou, X. D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703233 · Cited by 23
Jungwirth, G., Yu, T., Liu, F., Cao, J., Eddine, M. A., Moustafa, M., Abdollahi, A., Warta, R., Unterberg, A. W., & Herold‐Mende, C. C. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2085 · Cited by 22
Moscvin, M., Liacos, C., Chen, T., Theodorakakou, F., Fotiou, D., Hossain, S., Rowell, S. M., Leblebjian, H., Regan, E. M., Czarnecki, P. G., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00802-0 · Cited by 21
Self-citation
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.